Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 8:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gland Clear all
Active, not recruiting Not applicable Interventional

Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer

NCT03621644
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Stereotactic MRI-guided On-table Adaptive Radiation Therapy
Radiation
Lead sponsor
Viewray Inc.
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Miami, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Jun 11, 2026, 8:12 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Resveratrol and Human Hepatocyte Function in Cancer

NCT02261844
View directory record Official record
Conditions
Liver Cancer
Interventions
Resveratrol, Placebo
Dietary Supplement · Drug
Lead sponsor
University of Louisville
Other
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Jun 11, 2026, 8:12 AM EDT
Completed Phase 2 Interventional Results available

Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin

NCT00993616
View directory record Official record
Conditions
Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Interventions
belinostat, carboplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
81
States / cities
Hartford, Connecticut • New Britain, Connecticut • Lewes, Delaware + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Jun 11, 2026, 8:12 AM EDT
Terminated Phase 1 Interventional

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

NCT04244552
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Acral Lentiginous Melanoma, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, Esophageal Squamous Cell Carcinoma, Urothelial Carcinoma, DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Melanoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer
Interventions
ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD)
Biological · Drug
Lead sponsor
Atreca, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Jun 11, 2026, 8:12 AM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck

NCT03325465
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Pembrolizumab, Epacadostat
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2019 · Synced Jun 11, 2026, 8:12 AM EDT
Recruiting Phase 1Phase 2 Interventional

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

NCT06782932
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
AGEN2373, Balstilimab, Cyclophosphamide, GVAX, AGEN2373 (RP2D), mKRASvax
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Jun 11, 2026, 8:12 AM EDT
Completed Phase 2 Interventional Results available

Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies

NCT01079832
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Sarcoma, Ovarian Stromal Cancer, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Uterine Sarcoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Uterine Sarcoma, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IV Endometrial Carcinoma, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Uterine Sarcoma, Stage IV Vulvar Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer
Interventions
stereotactic radiosurgery, quality-of-life assessment
Radiation · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Jun 11, 2026, 8:12 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma

NCT01192555
View directory record Official record
Conditions
Neuroblastoma
Interventions
Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells, Cytoxan
Biological · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Jun 11, 2026, 8:12 AM EDT
Not yet recruiting Phase 2 Interventional

PDT For Induction Therapy For Head And Neck Cancer

NCT07214987
View directory record Official record
Conditions
Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
Toripalimab-tpzi, Cisplatin, Docetaxel
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jun 11, 2026, 8:12 AM EDT
Completed Not applicable Interventional

Prospective Randomized Controlled Trial Comparing Water and Air Colonoscopy in a Community Based Setting

NCT01729416
View directory record Official record
Conditions
Tubular Adenoma, Colon Cancer, Hyperplastic Polyp
Interventions
Water Exchange Colonoscopy, Air Colonoscopy
Other
Lead sponsor
University of California, Davis
Other
Eligibility
50 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Elk Grove, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Jun 11, 2026, 8:12 AM EDT
Terminated Phase 1Phase 2 Interventional

Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM

NCT02085304
View directory record Official record
Conditions
Glioblastoma
Interventions
Gross total resection and Gliadel(R) wafers implanted, GammaKnife(R) stereotactic Radiosurgery, Standard fractionated radiation therapy, Temozolomide
Procedure · Radiation · Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Jun 11, 2026, 8:12 AM EDT
Recruiting Phase 2 Interventional

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

NCT07126158
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Cancer of the Pancreas, Pancreas Cancer, Pancreatic Cancer
Interventions
Stereotactic body radiotherapy, Defactinib, Avutometinib
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jun 11, 2026, 8:12 AM EDT
Completed Not applicable Interventional Results available

Hatha Yoga in Improving Physical Activity, Inflammation, Fatigue, and Distress in Breast Cancer Survivors

NCT00486525
View directory record Official record
Conditions
Breast Cancer, Depression, Fatigue, Pain
Interventions
Yoga Therapy
Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 4, 2014 · Synced Jun 11, 2026, 8:12 AM EDT
Recruiting No phase listed Observational

Project: Every Child for Younger Patients With Cancer

NCT02402244
View directory record Official record
Conditions
Adrenal Gland Pheochromocytoma, Carcinoma In Situ, Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Kidney Neoplasm, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Desmoid Fibromatosis, Ganglioneuroma, Lymphoproliferative Disorder, Malignant Neoplasm, Malignant Solid Neoplasm, Melanocytic Neoplasm, Myeloproliferative Neoplasm, Neoplasm of Uncertain Malignant Potential, Neuroendocrine Neoplasm, Stromal Neoplasm
Interventions
Cytology Specimen Collection Procedure, Medical Chart Review
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 25 Years
Enrollment
75,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
245
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 176 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 11, 2026, 8:12 AM EDT
Completed Phase 3 Interventional Results available

A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma

NCT01865747
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Cabozantinib tablets, Everolimus (Afinitor) tablets
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
59
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Jun 11, 2026, 8:12 AM EDT
Terminated Phase 2 Interventional Results available

Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer

NCT01003938
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Topotecan, Erlotinib
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Jun 11, 2026, 8:12 AM EDT
Not yet recruiting Not applicable Interventional

A Study for Cerebral Open Flow Microperfusion

NCT07089758
View directory record Official record
Conditions
Glioma, Glioblastoma
Interventions
Cerebral open flow microperfusion
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jun 11, 2026, 8:12 AM EDT
Completed Phase 2 Interventional Results available

PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation

NCT01402063
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
PPX (CT2103), Temozolomide
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
La Jolla, California • Scarborough, Maine • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Jun 11, 2026, 8:12 AM EDT
Recruiting Early Phase 1 Interventional

Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%

NCT06645821
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
EVO101
Drug
Lead sponsor
Virginia Clinical Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Jun 11, 2026, 8:12 AM EDT
Recruiting Phase 2 Interventional

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

NCT05655949
View directory record Official record
Conditions
Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic, Metastatic Intrahepatic Cholangiocarcinoma
Interventions
Gemcitabine, Cisplatin, Durvalumab, Yttrium-90
Drug · Radiation
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jun 11, 2026, 8:12 AM EDT
Completed Phase 1Phase 2 Interventional

Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme

NCT00003417
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
218
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Jun 11, 2026, 8:12 AM EDT
Completed Not applicable Interventional Results available

Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor

NCT02944617
View directory record Official record
Conditions
Diarrhea, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions
Laboratory Biomarker Analysis, Micronutrient-Fortified Probiotic Yogurt, VEGF-TKI
Other · Dietary Supplement · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Jun 11, 2026, 8:12 AM EDT
Not listed Not applicable Interventional

Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery

NCT00671476
View directory record Official record
Conditions
Breast Cancer
Interventions
pegylated liposomal doxorubicin hydrochloride, DNA methylation analysis, TdT-mediated dUTP nick end labeling assay, fluorescence in situ hybridization, loss of heterozygosity analysis, polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, breast duct lavage, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Dr. Susan Love Research Foundation
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
Eureka, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Jun 11, 2026, 8:12 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

NCT03127098
View directory record Official record
Conditions
Thyroid Cancer, Colon Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer
Interventions
ETBX-011, ALT-803
Biological
Lead sponsor
NantCell, Inc.
Industry
Eligibility
21 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jun 11, 2026, 8:12 AM EDT